Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:37:38 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Bioharvest Sciences Inc
Symbol BHSC
Shares Issued 478,588,168
Close 2023-07-14 C$ 0.205
Market Cap C$ 98,110,574
Recent Sedar+ Documents

Bioharvest to settle $21,000 of debt by issuing shares

2023-07-14 16:54 ET - News Release

Subject: Release/News Attached Word Document File: '\\swfile\EmailIn\20230714 134933 Attachment 071423 BHSC NR Share for Debt Final.docx' CSE:BHSC - FSE:8MV - OTC: CNVCF OFSE:8MV `NR: 071423-1 BIOHARVEST SCIENCES INC. ANNOUNCES PAYMENT OF SHARES FOR DEBT VANCOUVER, BC, JULY 14, 2023 - BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) announces today that it has agreed to settle $21,000 dollars of outstanding indebtedness by the issuance of 100,000 shares at a deemed price of $0.21 per share, subject to regulatory approval. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at an industrial scale, without the need to grow the plant itself. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals - nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (API's) that focus on specific medical indications. Visit: www.bioharvest.com. BioHarvest Sciences Inc. Ilan Sobel, Chief Executive Officer For further information, please contact: Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186 Email: dave@bioharvest.com Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

© 2026 Canjex Publishing Ltd. All rights reserved.